Clinical trial results:
A Double -Blind, Randomized, Placebo-Controlled, Parallel, Dose-Ranging Study to Evaluate the Efficacy and Safety of PF-00547659 in Subjects With Moderate to Severe Ulcerative Colitis (Turandot)

Summary

EudraCT number	2012-002030-37
Trial protocol	BE NL IT PL SK HU CZ DE SE AT ES BG HR
Global end of trial date	04 February 2016

Results information

Result version number	v1 (current)
This version publication date	03 December 2016
First version publication date	03 December 2016

Trial information

Trial identification

Sponsor protocol code	A7281009

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01620255
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc
Sponsor organisation address	235 E 42nd Street, New York, United States, 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc, 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc, 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 February 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 September 2014
Global end of trial reached?	Yes
Global end of trial date	04 February 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study was to characterize the dose response and efficacy of PF-00547659 in inducing clinical remission based upon Mayo Score in subjects with moderate to severe ulcerative colitis (UC).

Protection of trial subjects:

This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed; in particular, those affording greater protection to the safety of study subjects.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 November 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 18
Country: Number of subjects enrolled	Austria: 2
Country: Number of subjects enrolled	Belgium: 18
Country: Number of subjects enrolled	Bulgaria: 2
Country: Number of subjects enrolled	Canada: 18
Country: Number of subjects enrolled	Czech Republic: 14
Country: Number of subjects enrolled	France: 31
Country: Number of subjects enrolled	Germany: 3
Country: Number of subjects enrolled	Hungary: 1
Country: Number of subjects enrolled	Israel: 8
Country: Number of subjects enrolled	Italy: 21
Country: Number of subjects enrolled	Korea, Republic of: 23
Country: Number of subjects enrolled	Netherlands: 8
Country: Number of subjects enrolled	New Zealand: 2
Country: Number of subjects enrolled	Poland: 47
Country: Number of subjects enrolled	Russian Federation: 2
Country: Number of subjects enrolled	Serbia: 15
Country: Number of subjects enrolled	Slovakia: 13
Country: Number of subjects enrolled	South Africa: 3

Country: Number of subjects enrolled	Spain: 8
Country: Number of subjects enrolled	United States: 100
Worldwide total number of subjects	357
EEA total number of subjects	168

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	354
From 65 to 84 years	3
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The study was conducted at 21 countries. Subjects were males/females between the ages of 18 and 65 years, inclusive, at the time of informed consent. Subjects were to have a diagnosis of UC for more than or equal to (>=) 3 months and a flexible sigmoidoscopy/colonoscopy indicative of active UC during Screening.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

The subjects, investigators, and Sponsor were blinded to randomized study treatments.

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Subjects received placebo (pbo) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 centimeters (cm) apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subcutaneous injection on the anterolateral right or left thighs

Arm title	PF-00547659 7.5 mg

Arm description:

Subjects received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Arm type	Experimental
Investigational medicinal product name	PF-00547659
Investigational medicinal product code	PF-00547659
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subcutaneous injection on anterolateral right or left thighs

Arm title	PF-00547659 22.5 mg

Arm description:

Subjects received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28,
and 56, following the completion of most study procedures. Subjects were administered PF-00547659 22.5 mg SC in
the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Arm type	Experimental
Investigational medicinal product name	PF-00547659
Investigational medicinal product code	PF-00547659
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subcutaneous injection on anterolateral right or left thighs

Arm title	PF-00547659 75 mg

Arm description:

Subjects received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 75 mg SC in
the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Arm type	Experimental
Investigational medicinal product name	PF-00547659
Investigational medicinal product code	PF-00547659
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subcutaneous injection on anterolateral right or left thighs

Arm title	PF-00547659 225 mg

Arm description:

Subjects received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Arm type	Experimental
Investigational medicinal product name	PF-00547659
Investigational medicinal product code	PF-00547659
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subcutaneous injection on anterolateral right or left thighs

Number of subjects in period 1	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg
Started	73	71	72
Completed	69	65	70
Not completed	4	6	2
Consent withdrawn by subject	4	1	1
Adverse event, non-fatal	-	4	-
Withdrawn at discretion of investigator	-	-	-
Non-compliance	-	1	-
Subject underwent fecal transplant	-	-	1

Number of subjects in period 1	PF-00547659 75 mg	PF-00547659 225 mg
Started	71	70
Completed	68	64
Not completed	3	6
Consent withdrawn by subject	2	4
Adverse event, non-fatal	1	1
Withdrawn at discretion of investigator	-	1
Non-compliance	-	-
Subject underwent fecal transplant	-	-

Baseline characteristics

Reporting groups	
Reporting group title	Placebo
Reporting group description:	
Subjects received placebo (pbo) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 centimeters (cm) apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.	
Reporting group title	PF-00547659 7.5 mg
Reporting group description:	
Subjects received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.	
Reporting group title	PF-00547659 22.5 mg
Reporting group description:	
Subjects received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.	
Reporting group title	PF-00547659 75 mg
Reporting group description:	
Subjects received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.	
Reporting group title	PF-00547659 225 mg
Reporting group description:	
Subjects received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.	

Reporting group values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg
Number of subjects	73	71	72
Age Categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	72	71	71
From 65-84 years	1	0	1

85 years and over	0	0	0

Age Continuous			
Units: years			
arithmetic mean	38.6	41.3	42.1
standard deviation	± 12.7	± 12.5	± 14.7
Gender Categorical			
Units: Subjects			
Female	29	32	26
Male	44	39	46

Reporting group values	PF-00547659 75 mg	PF-00547659 225 mg	Total
Number of subjects	71	70	357
Age Categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	71	69	354
From 65-84 years	0	1	3
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	37.7	41.3	
standard deviation	± 12.4	± 13.2	-
Gender Categorical			
Units: Subjects			
Female	34	28	149
Male	37	42	208

End points

End points reporting groups

Reporting group title	Placebo

Reporting group description:

Subjects received placebo (pbo) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 centimeters (cm) apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Reporting group title	PF-00547659 7.5 mg

Reporting group description:

Subjects received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Reporting group title	PF-00547659 22.5 mg

Reporting group description:

Subjects received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28,
and 56, following the completion of most study procedures. Subjects were administered PF-00547659 22.5 mg SC in
the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Reporting group title	PF-00547659 75 mg

Reporting group description:

Subjects received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 75 mg SC in
the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Reporting group title	PF-00547659 225 mg

Reporting group description:

Subjects received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Primary: Percentage of subjects in clinical remission at Week 12

End point title	Percentage of subjects in clinical remission at Week 12

End point description:

Clinical remission was defined as a Total Mayo Score of less than or equal to (<=) 2 points with no individual subscore exceeding 1 point and rectal bleed subscore of 0 or 1. The MayoScore is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.

End point type	Primary

End point timeframe:

Week 12

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	72	71
Units: percentage of subjects				
number (confidence interval 90%)				
Centrally read (CR)	2.7 (0.7 to 7.6)	11.3 (5.7 to 18.8)	16.7 (9.9 to 25.4)	15.5 (9.5 to 23.6)
Locally read (LR)	5.5 (2.4 to 12)	14.1 (7.8 to 22)	23.6 (15.6 to 33.1)	18.3 (11.9 to 27.1)

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: percentage of subjects				
number (confidence interval 90%)				
Centrally read (CR)	5.7 (2.5 to 12.5)			
Locally read (LR)	12.9 (7.3 to 21.1)			

Statistical analyses

Statistical analysis title	PF-00547659 7.5 mg versus (vs) placebo, CR
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0213 [1]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.08
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.019
upper limit	0.14

Notes:

[1] - 1-sided p-value

Statistical analysis title	PF-00547659 22.5 mg vs placebo, CR
Comparison groups	Placebo v PF-00547659 22.5 mg

Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0025 [2]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.128
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.056
upper limit	0.199

Notes:

[2] - 1-sided p-value

Statistical analysis title	PF-00547659 75 mg vs placebo, CR
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.004 [3]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.118
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.048
upper limit	0.188

Notes:

[3] - 1-sided p-value

Statistical analysis title	PF-00547659 225 mg vs placebo, CR
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1803 [4]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.026
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.012
upper limit	0.064

Notes:

[4] - 1-sided p-value

Statistical analysis title	PF-00547659 7.5 mg vs placebo, LR

Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0582 [5]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.08
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.002
upper limit	0.159

Notes:

[5] - 1-sided p-value

Statistical analysis title	PF-00547659 22.5 mg vs placebo, LR
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0014 [6]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.178
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.083
upper limit	0.272

Notes:

[6] - 1-sided p-value

Statistical analysis title	PF-00547659 75 mg vs placebo, LR
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0125 [7]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.122
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.036
upper limit	0.208

Notes:

[7] - 1-sided p-value

Statistical analysis title	PF-00547659 225 mg vs placebo, LR
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0927 [8]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.066
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.009
upper limit	0.142

Notes:

[8] - 1-sided p-value

Secondary: Percentage of subjects with clinical response at Week 12

End point title	Percentage of subjects with clinical response at Week 12

End point description:

Clinical response was defined as a decrease from baseline of at least 3 points in Total Mayo Score with at least a 30 percent (%) change, accompanied by at least 1 point decrease or absolute score of 0 or 1 in rectal bleeding subscore. The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. "n" signifies the number of subjects evaluable for the specified category.

End point type	Secondary

End point timeframe:

Week 12

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	72	71
Units: percentage of subjects				
number (confidence interval 90%)				
Centrally read (CR) (n=73,71,72,71,70)	28.8 (20.2 to 37.8)	38 (28.4 to 47.6)	54.2 (44.2 to 64.2)	45.1 (35 to 55.3)
Locally read (LR) (n=73,70,72,70,70)	32.9 (24.2 to 42.3)	38.6 (28.8 to 48.1)	54.2 (44.2 to 64.2)	48.6 (38.2 to 59)

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: percentage of subjects				

number (confidence interval 90%)				
Centrally read (CR) (n=73,71,72,71,70)	50 (39.6 to 60.4)			
Locally read (LR) (n=73,70,72,70,70)	51.4 (41 to 61.8)			

Statistical analyses

Statistical analysis title	PF-00547659 7.5 mg vs placebo, CR
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1379 [9]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.089
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.037
upper limit	0.214

Notes:

[9] - 1-sided p-value

Statistical analysis title	PF-00547659 22.5 mg vs placebo, CR
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0011 [10]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.254
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.121
upper limit	0.388

Notes:

[10] - 1-sided p-value

Statistical analysis title	PF-00547659 75 mg vs placebo, CR
Comparison groups	Placebo v PF-00547659 75 mg

Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0239 [11]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.163
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.032
upper limit	0.293

Notes:

[11] - 1-sided p-value

Statistical analysis title	PF-00547659 225 mg vs placebo, CR
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0052 [12]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.213
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.08
upper limit	0.347

Notes:

[12] - 1-sided p-value

Statistical analysis title	PF-00547659 7.5 mg vs placebo, LR
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.2617 [13]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.056
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.075
upper limit	0.186

Notes:

[13] - 1-sided p-value

Statistical analysis title	PF-00547659 22.5 mg vs placebo, LR

Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0058 [14]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.212
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.077
upper limit	0.347

Notes:

[14] - 1-sided p-value

Statistical analysis title	PF-00547659 75 mg vs placebo, LR
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0326 [15]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.156
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.022
upper limit	0.29

Notes:

[15] - 1-sided p-value

Statistical analysis title	PF-00547659 225 mg vs placebo, LR
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0145 [16]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.185
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.05
upper limit	0.32

Notes:

[16] - 1-sided p-value

Secondary: Percentage of subjects with mucosal healing at Week 12

End point title	Percentage of subjects with mucosal healing at Week 12

End point description:

Mucosal healing was defined as absolute Mayo subscore for endoscopy of 0 or 1. The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central readerwere considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.

End point type	Secondary

End point timeframe:

Week 12

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	72	71
Units: percentage of subjects				
number (confidence interval 90%)				
Centrally read (CR)	8.2 (3.6 to 15.4)	15.5 (9.5 to 23.6)	27.8 (19.5 to 37.1)	25.4 (17.1 to 35)
Locally read (LR)	21.9 (14.9 to 31.4)	22.5 (15.4 to 31.6)	37.5 (28 to 47.2)	35.2 (25.8 to 44.7)

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: percentage of subjects				
number (confidence interval 90%)				
Centrally read (CR)	14.3 (8 to 22.3)			
Locally read (LR)	28.6 (20.2 to 38.2)			

Statistical analyses

Statistical analysis title	PF-00547659 7.5 mg vs placebo, CR
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0618 [17]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.081

Confidence interval	
level	90 %
sides	2-sided
lower limit	0
upper limit	0.162

Notes:

[17] - 1-sided p-value

Statistical analysis title	PF-00547650 22.5 mg vs placebo, CR
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0009 [18]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.187
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.091
upper limit	0.284

Notes:

[18] - 1-sided p-value

Statistical analysis title	PF-00547659 75 mg vs placebo, CR
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0027 [19]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.159
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.068
upper limit	0.25

Notes:

[19] - 1-sided p-value

Statistical analysis title	PF-00547659 225 mg vs placebo, CR
Comparison groups	Placebo v PF-00547659 225 mg

Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0999 [20]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.069
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.013
upper limit	0.151

Notes:

[20] - 1-sided p-value

Statistical analysis title	PF-00547659 7.5 mg vs placebo, LR
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.5225 [21]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.001
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.111
upper limit	0.114

Notes:

[21] - 1-sided p-value

Statistical analysis title	PF-00547659 22.5 mg vs placebo, LR
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0246 [22]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.154
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.03
upper limit	0.278

Notes:

[22] - 1-sided p-value

Statistical analysis title	PF-00547659 75 mg vs placebo, LR

Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0464 [23]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.13
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.008
upper limit	0.253

Notes:

[23] - 1-sided p-value

Statistical analysis title	PF-00547659 225 mg vs placebo, LR
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.2 [24]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.066
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.053
upper limit	0.186

Notes:

[24] - 1-sided p-value

Secondary: Percentage of subjects with absolute Partial Mayo Score of less than or equal to (<=) 2 with no individual subscore more than (>) 1 at Weeks 4, 8, and 12

End point title	Percentage of subjects with absolute Partial Mayo Score of less than or equal to (<=) 2 with no individual subscore more than (>) 1 at Weeks 4, 8, and 12

End point description:

An absolute Partial Mayo Score of <=2 corresponds to remission. However, this endpoint was incorrectly stated in the protocol and instead of "absolute Partial MayoScore <=2", it was stated as "change from baseline in Partial Mayo Score <=2". As this endpoint was incorrectly stated in the protocol, no analyses were done and no data are presented.

End point type	Secondary

End point timeframe:

Weeks 4, 8, and 12

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[25]	0[26]	0[27]	0[28]
Units: percentage of subjects				
number (confidence interval 90%)	(to)	(to)	(to)	(to)

Notes:

[25] - This endpoint was incorrectly stated in the protocol, no analyses were done.

[26] - This endpoint was incorrectly stated in the protocol, no analyses were done.

[27] - This endpoint was incorrectly stated in the protocol, no analyses were done.

[28] - This endpoint was incorrectly stated in the protocol, no analyses were done.

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	0[29]			
Units: percentage of subjects				
number (confidence interval 90%)	(to)			

Notes:

[29] - This endpoint was incorrectly stated in the protocol, no analyses were done.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Total Mayo Score at Week 12

End point title	Change from baseline in Total Mayo Score at Week 12

End point description:

The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. "n" signifies the number of evaluable subjects in that specified category.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	72	71
Units: units on a scale				
arithmetic mean (standard deviation)				
Centrally read (CR) baseline (n=73,71,72,71,70)	8.4 (± 1.71)	8.7 (± 1.65)	8.1 (± 1.63)	8.4 (± 1.94)
Centrally read change (n=67,63,69,67,63)	-1.5 (± 2.42)	-2.4 (± 2.78)	-2.9 (± 2.49)	-2.5 (± 2.74)
Locally read (LR) baseline (n=73,70,72,70,70)	8.4 (± 1.72)	8.8 (± 1.59)	8.1 (± 1.72)	8.3 (± 1.99)
Locally read change (n=67,62,70,66,64)	-1.7 (± 2.55)	-2.7 (± 3.05)	-3.1 (± 2.7)	-2.7 (± 2.92)

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: units on a scale				
arithmetic mean (standard deviation)				
Centrally read (CR) baseline (n=73,71,72,71,70)	8.7 (± 1.6)			
Centrally read change (n=67,63,69,67,63)	-2.9 (± 2.78)			
Locally read (LR) baseline (n=73,70,72,70,70)	8.6 (± 1.62)			
Locally read change (n=67,62,70,66,64)	-3.1 (± 3.07)			

Statistical analyses

Statistical analysis title	PF-00547659 7.5 mg vs placebo, CR change
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other[30]
P-value	= 0.0494
Method	ANCOVA
Parameter estimate	Least Squares Mean (LSM) Difference
Point estimate	-0.88
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.623
upper limit	-0.145

Notes:

[30] - Analysis of covariance (ANCOVA) with model terms: treatment group, baseline, status of anti-tumor necrosis factor (TNF) therapy experience.

Statistical analysis title	PF-00547659 22.5 mg vs placebo, CR change
Statistical analysis description:	
ANCOVA with model terms: treatment group, baseline, status of anti TNF therapy experience	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0005
Method	ANCOVA
Parameter estimate	LSM Difference
Point estimate	-1.53

Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.254
upper limit	-0.809

Statistical analysis title	PF-00547659 75 mg vs placebo, CR change
Statistical analysis description:	
ANCOVA with modelterms: treatment group, baseline, status of anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0117
Method	ANCOVA
Parameter estimate	LSM Difference
Point estimate	-1.12
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.845
upper limit	-0.39

Statistical analysis title	PF-00547659 225 mg vs placebo, CR change
Statistical analysis description:	
ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0049
Method	ANCOVA
Parameter estimate	LSM Difference
Point estimate	-1.27
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.016
upper limit	-0.533

Statistical analysis title	PF-00547659 7.5 mg vs placebo, LR change
Statistical analysis description:	
ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg

Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0543
Method	ANCOVA
Parameter estimate	LSM Difference
Point estimate	-0.94
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.737
upper limit	-0.137

Statistical analysis title	PF-00547659 22.5 mg vs placebo, LR change
Statistical analysis description:	
ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0008
Method	ANCOVA
Parameter estimate	LSM Difference
Point estimate	-1.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.372
upper limit	-0.819

Statistical analysis title	PF-00547659 75 mg vs placebo, LR change
Statistical analysis description:	
ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0255
Method	ANCOVA
Parameter estimate	LSM Difference
Point estimate	-1.07
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.858
upper limit	-0.284

Statistical analysis title	PF-00547659 225 mg vs placebo, LR change
Statistical analysis description:	
ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience	
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0079
Method	ANCOVA
Parameter estimate	LSM Difference
Point estimate	-1.29
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.082
upper limit	-0.493

Secondary: Percentage of subjects with change from baseline in individual Mayo subscores - stool frequency, rectal bleeding, and Physician's Global Assessment (PGA) - at Weeks 4, 8, and 12

End point title	Percentage of subjects with change from baseline in individual Mayo subscores - stool frequency, rectal bleeding, and Physician's Global Assessment (PGA) - at Weeks 4, 8, and 12

End point description:

The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency [freq], rectal bleeding, PGA, findings on flexible sigmoidoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. Changes from baseline in the subscore of less than (<) 0, 0, and >0 corresponded to improvement (imp), no change (NC), and worsening (wors) in that specific subscore. "n" signifies the number of evaluable subjects at that specific time point for that endpoint.

End point type	Secondary

End point timeframe:

Baseline; Weeks (W) 4, 8, and 12

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	72	71
Units: percentage of subjects				
number (not applicable)				
Imp in Stool frequency, W4 (n=67,64,71,69,65)	26.87	46.88	36.62	30.43
NC in Stool frequency, W4 (n=67,64,71,69,65)	59.7	42.19	60.56	63.77

Wors in Stool frequency, W4 (n=67,64,71,69,65)	13.43	10.94	2.82	5.8
Imp in Stool frequency, W8 (n=71,63,71,69,68)	28.17	49.21	43.66	49.28
NC in Stool frequency, W8 (n=71,63,71,69,68)	60.56	42.86	53.52	46.38
Wors in Stool frequency, W8 (n=71,63,71,69,68)	11.27	7.94	2.82	4.35
Imp in Stool frequency, W12 (n=67,63,71,68,64)	35.82	49.21	56.34	45.59
NC in Stool frequency, W12 (n=67,63,71,68,64)	52.24	41.27	38.03	48.53
Wors in Stool frequency, W12 (n=67,63,71,68,64)	11.94	9.52	5.63	5.88
Imp in Rectal Bleeding, W4 (n=67,64,71,69,65)	22.39	48.44	42.25	42.03
NC in Rectal Bleeding, W4 (n=67,64,71,69,65)	62.69	42.19	57.75	53.62
Wors in Rectal Bleeding, W4 (n=67,64,71,69,65)	14.93	9.38	0	4.35
Imp in Rectal Bleeding, W8 (n=71,63,71,69,68)	33.8	50.79	40.85	46.38
NC in Rectal Bleeding, W8 (n=71,63,71,69,68)	54.93	36.51	50.7	44.93
Wors in Rectal Bleeding, W8 (n=71,63,71,69,68)	11.27	12.7	8.45	8.7
Imp in Rectal Bleeding, W12 (n=67,63,71,68,64)	37.31	53.97	50.7	47.06
NC in Rectal Bleeding, W12 (n=67,63,71,68,64)	50.75	34.92	42.25	45.59
Wors in Rectal Bleeding, W12 (n=67,63,71,68,64)	11.94	11.11	7.04	7.35
Imp in PGA, W4 (n=67,64,71,69,65)	47.76	57.81	56.34	56.52
NC in PGA, W4 (n=67,64,71,69,65)	49.25	34.38	39.44	42.03
Wors in PGA, W4 (n=67,64,71,69,65)	2.99	7.81	4.23	1.45
Imp in PGA, W8 (n=71,63,71,69,68)	59.15	61.9	66.2	62.32
NC in PGA, W8 (n=71,63,71,69,68)	33.8	30.16	30.99	37.68
Wors in PGA, W8 (n=71,63,71,69,68)	7.04	7.94	2.82	0
Imp in PGA, W12 (n=67,63,71,68,64)	50.75	61.9	64.79	55.88
NC in PGA, W12 (n=67,63,71,68,64)	43.28	31.75	32.39	39.71
Wors in PGA, W12 (n=67,63,71,68,64)	5.97	6.35	2.82	4.41

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: percentage of subjects				
number (not applicable)				
Imp in Stool frequency, W4 (n=67,64,71,69,65)	43.08			
NC in Stool frequency, W4 (n=67,64,71,69,65)	52.31			
Wors in Stool frequency, W4 (n=67,64,71,69,65)	4.62			
Imp in Stool frequency, W8 (n=71,63,71,69,68)	51.47			

NC in Stool frequency, W8 (n=71,63,71,69,68)	48.53			
Wors in Stool frequency, W8 (n=71,63,71,69,68)	0			
Imp in Stool frequency, W12 (n=67,63,71,68,64)	56.25			
NC in Stool frequency, W12 (n=67,63,71,68,64)	37.5			
Wors in Stool frequency, W12 (n=67,63,71,68,64)	6.25			
Imp in Rectal Bleeding, W4 (n=67,64,71,69,65)	49.23			
NC in Rectal Bleeding, W4 (n=67,64,71,69,65)	44.62			
Wors in Rectal Bleeding, W4 (n=67,64,71,69,65)	6.15			
Imp in Rectal Bleeding, W8 (n=71,63,71,69,68)	64.71			
NC in Rectal Bleeding, W8 (n=71,63,71,69,68)	33.82			
Wors in Rectal Bleeding, W8 (n=71,63,71,69,68)	1.47			
Imp in Rectal Bleeding, W12 (n=67,63,71,68,64)	60.94			
NC in Rectal Bleeding, W12 (n=67,63,71,68,64)	35.94			
Wors in Rectal Bleeding, W12 (n=67,63,71,68,64)	3.13			
Imp in PGA, W4 (n=67,64,71,69,65)	60			
NC in PGA, W4 (n=67,64,71,69,65)	35.38			
Wors in PGA, W4 (n=67,64,71,69,65)	4.62			
Imp in PGA, W8 (n=71,63,71,69,68)	67.65			
NC in PGA, W8 (n=71,63,71,69,68)	30.88			
Wors in PGA, W8 (n=71,63,71,69,68)	1.47			
Imp in PGA, W12 (n=67,63,71,68,64)	57.81			
NC in PGA, W12 (n=67,63,71,68,64)	32.81			
Wors in PGA, W12 (n=67,63,71,68,64)	9.38			

Statistical analyses

Statistical analysis title	PF-00547659 7.5 mg vs placebo, Stool Freq, W4
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other[31]
P-value	= 0.1016
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.25
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.511
upper limit	0.001

Notes:

[31] - Linear Mixed Model (LMM) with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Statistical analysis title	PF-00547659 22.5 mg vs placebo, Stool Freq, W4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0654
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.28
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.529
upper limit	-0.03

Statistical analysis title	PF-00547659 75 mg vs placebo, Stool Freq, W4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.15
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.22
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.472
upper limit	0.031

Statistical analysis title	PF-00547659 225 mg vs placebo, Stool Freq, W4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 225 mg

Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0132
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.38
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.637
upper limit	-0.129

Statistical analysis title	PF-00547659 7.5 mg vs placebo, Stool Freq, W8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0526
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.555
upper limit	-0.046

Statistical analysis title	PF-00547659 22.5 mg vs placebo, Stool Freq, W8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0422
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.31

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.554
upper limit	-0.058

Statistical analysis title	PF-00547659 75 mg vs placebo, Stool Frequency, W8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.011
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.39
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.637
upper limit	-0.137

Statistical analysis title	PF-00547659 225 mg vs placebo, Stool Freq, W8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.001
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.755
upper limit	-0.254

Statistical analysis title	PF-00547659 7.5 mg vs placebo, Stool Freq, W12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1611
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.22
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.475
upper limit	0.038

Statistical analysis title	PF-00547659 22.5 mg vs placebo, Stool Freq, W12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0186
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.36
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.608
upper limit	-0.108

Statistical analysis title	PF-00547659 75 mg vs placebo, Stool Freq, W12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1647
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.21

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.465
upper limit	0.039

Statistical analysis title	PF-00547659 225 mg vs placebo, Stool Freq, W12
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0231
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.35
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.607
upper limit	-0.097

Statistical analysis title	PF-00547659 7.5 mg vs placebo, Rectal Bleeding, W4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0002
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.46
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.658
upper limit	-0.26

Statistical analysis title	PF-00547659 22.5 mg vs pbo, Rectal Bleeding, W4

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.52
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.71
upper limit	-0.322

Statistical analysis title	PF-00547659 75 mg vs pbo, Rectal Bleeding, W4

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.49
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.686
upper limit	-0.295

Statistical analysis title	PF-00547659 225 mg vs pbo, Rectal Bleeding, W4

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0012
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.39

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.587
upper limit	-0.192

Statistical analysis title	PF-00547659 7.5 mg vs pbo, Rectal Bleeding, W8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0207
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.28
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.475
upper limit	-0.081

Statistical analysis title	PF-00547659 22.5 mg vs pbo, Rectal Bleeding, W8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0402
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.24
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.432
upper limit	-0.048

Statistical analysis title	PF-00547659 75 mg vs pbo, Rectal Bleeding, W8

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0071
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.32
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.511
upper limit	-0.124

Statistical analysis title	PF-00547659 225 mg vs pbo, Rectal Bleeding, W8

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.47
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.664
upper limit	-0.275

Statistical analysis title	PF-00547659 7.5 mg vs pbo, Rectal Bleeding, W12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0395
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.25

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.449
upper limit	-0.05

Statistical analysis title	PF-00547659 22.5 mg vs pbo, Rectal Bleeding, W12
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0073
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.32
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.511
upper limit	-0.123

Statistical analysis title	PF-00547659 75 mg vs pbo, Rectal Bleeding, W12
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0413
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.24
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.439
upper limit	-0.047

Statistical analysis title	PF-00547659 225 mg vs pbo, Rectal Bleeding, W12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0008
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.602
upper limit	-0.206

Statistical analysis title	PF-00547659 7.5 mg vs pbo, PGA, W4

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1862
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.19
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.421
upper limit	0.046

Statistical analysis title	PF-00547659 22.5 mg vs pbo, PGA, W4

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience

Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0998
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.23

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.455
upper limit	0

Statistical analysis title	PF-00547659 75 mg vs pbo, PGA, W4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1085
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.22
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.453
upper limit	0.006

Statistical analysis title	PF-00547659 225 mg vs pbo, PGA, W4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience	
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.3161
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.14
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.372
upper limit	0.09

Statistical analysis title	PF-00547659 7.5 mg vs pbo, PGA, W8

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience

Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.4962
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.328
upper limit	0.136

Statistical analysis title	PF-00547659 22.5 mg vs pbo, PGA, W8

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience

Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0371
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.29
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.512
upper limit	-0.06

Statistical analysis title	PF-00547659 75 mg vs pbo, PGA, W8

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience

Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1212
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.21

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.441
upper limit	0.013

Statistical analysis title	PF-00547650 225 mg vs pbo, PGA, W8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience	
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.187
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.18
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.41
upper limit	0.045

Statistical analysis title	PF-00547659 7.5 mg vs pbo, PGA, W12
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience	
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1133
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.23
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.459
upper limit	0.009

Statistical analysis title	PF-00547659 22.5 mg vs pbo, PGA, W12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience

Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0022
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.43
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.653
upper limit	-0.198

Statistical analysis title	PF-00547659 75 mg vs pbo, PGA, W12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience

Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0788
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.25
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.475
upper limit	-0.016

Statistical analysis title	PF-00547659 225 mg vs pbo, PGA, W12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0717
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.25

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.485
upper limit	-0.022

Secondary: Percentage of subjects with change from baseline in individual Mayo subscore - findings on flexible sigmoidoscopy - at Week 12

End point title	Percentage of subjects with change from baseline in individual Mayo subscore - findings on flexible sigmoidoscopy - at Week 12

End point description:

The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, PGA, findings on flexible sigmoidoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. Changes from baseline in the subscore of <0, 0, and >0 corresponded to improvement (imp), no change (NC), and worsening (wors) in that specific subscore. "n" signifies the number of evaluable subjects at Week 12.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	72	71
Units: percentage of subjects				
number (not applicable)				
Imp (n=67,63,69,67,63)	25.37	28.57	47.83	47.76
NC (n=67,63,69,67,63)	61.19	60.32	49.28	46.27
Wors (n=67,63,69,67,63)	13.43	11.11	2.9	5.97

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: percentage of subjects				
number (not applicable)				
Imp (n=67,63,69,67,63)	39.68			
NC (n=67,63,69,67,63)	57.14			
Wors (n=67,63,69,67,63)	3.17			

Statistical analyses

Statistical analysis title	PF-00547659 7.5 mg vs placebo
Statistical analysis description:	
ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.5406
Method	ANCOVA
Parameter estimate	LSM Difference
Point estimate	-0.08
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.286
upper limit	0.131

Statistical analysis title	PF-00547659 22.5 mg vs placebo
Statistical analysis description:	
ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0007
Method	ANCOVA
Parameter estimate	LSM Difference
Point estimate	-0.42
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.628
upper limit	-0.221

Statistical analysis title	PF-00547659 75 mg vs placebo
Statistical analysis description:	
ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0063
Method	ANCOVA
Parameter estimate	LSM Difference
Point estimate	-0.34

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.549
upper limit	-0.137

Statistical analysis title	PF-00547659 225 mg vs placebo
Statistical analysis description:	
ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0748
Method	ANCOVA
Parameter estimate	LSM Difference
Point estimate	-0.23
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.436
upper limit	-0.018

Secondary: Percent change from baseline in fecal calprotectin at Weeks 4, 8, and 12	
End point title	Percent change from baseline in fecal calprotectin at Weeks 4, 8, and 12
End point description:	
Fecal calprotectin was one of the pharmacodynamic (PD) biomarkers of the study. "n" signifies the number of evaluable subjects at that specific time point.	
End point type	Secondary
End point timeframe:	
Baseline; Weeks 4, 8, and 12	

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	72	71
Units: percent change				
geometric mean (confidence interval 90%)				
Week 4 (n=62,57,68,67,60)	-25.62 (-43.49 to -2.09)	-40.21 (-55.56 to -19.54)	-23.5 (-44.27 to 5)	-46.22 (-61.46 to -24.95)
Week 8 (n=67,57,67,63,65)	-21.68 (-39.62 to 1.6)	-44.49 (-60.05 to -22.88)	-44.77 (-60.49 to -22.8)	-57.2 (-69.74 to -39.45)
Week 12 (n=61,55,64,64,59)	-22.59 (-42.68 to 4.54)	-56.34 (-69.39 to -37.72)	-58.41 (-72.26 to -37.65)	-56.72 (-71.67 to -33.88)

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: percent change				
geometric mean (confidence interval 90%)				
Week 4 (n=62,57,68,67,60)	-39.27 (-56.74 to -14.75)			
Week 8 (n=67,57,67,63,65)	-49.54 (-65.08 to -27.07)			
Week 12 (n=61,55,64,64,59)	-64.52 (-76.92 to -45.43)			

Statistical analyses

Statistical analysis title	PF-00547659 7.5 mg vs placebo, Week 4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.9744
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-1.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-101
upper limit	97.14

Statistical analysis title	PF-00547659 22.5 mg vs placebo, Week 4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg

Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.2023
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	74.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-21.77
upper limit	171.66

Statistical analysis title	PF-00547659 75 mg vs placebo, Week 4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.5808
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	32.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-65.09
upper limit	130.79

Statistical analysis title	PF-00547659 225 mg vs placebo, Week 4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.5388
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	37.6

Confidence interval	
level	90 %
sides	2-sided
lower limit	-63.12
upper limit	138.34

Statistical analysis title	PF-00547659 7.5 mg vs placebo, Week 8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.8902
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-8.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-106.24
upper limit	89.81

Statistical analysis title	PF-00547659 22.5 mg vs placebo, Week 8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.8616
Method	Mixed models analysis
Parameter estimate	LSM Differennce
Point estimate	10.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-86.14
upper limit	106.54

Statistical analysis title	PF-00547659 75 mg vs placebo, Week 8

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.5684
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-34.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-133.49
upper limit	64.79

Statistical analysis title	PF-00547659 225 mg vs placebo, Week 8

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.57
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	33.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-64.2
upper limit	131.86

Statistical analysis title	PF-00547659 7.5 mg vs placebo, Week 12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.6234
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-30

Confidence interval	
level	90 %
sides	2-sided
lower limit	-130.56
upper limit	70.57

Statistical analysis title	PF-00547659 22.5 mg vs placebo, Week 12
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.5474
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	36
Confidence interval	
level	90 %
sides	2-sided
lower limit	-62.44
upper limit	134.38

Statistical analysis title	PF-00547659 75 mg vs placebo, Week 12
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1918
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	78.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-20.48
upper limit	177.56

Statistical analysis title	PF-00547659 225 mg vs placebo, Week 12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.9615
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-104.88
upper limit	98.91

Secondary: Percent change from baseline in high sensitivity C-reactive protein (hsCRP) at Weeks 4, 8, and 12

End point title	Percent change from baseline in high sensitivity C-reactive protein (hsCRP) at Weeks 4, 8, and 12

End point description:

hsCRP was one of the PD biomarkers of the study. "n" signifies the number of evaluable subjects at that specific time point.

End point type	Secondary

End point timeframe:

Baseline; Weeks 4, 8, and 12

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	72	71
Units: percent change				
geometric mean (confidence interval 90%)				
Week 4 (n=67,64,69,71,65)	-11.6 (-25.69 to 5.17)	-19.17 (-34.22 to -0.67)	-26.9 (-39.41 to -11.82)	-35.21 (-49.1 to -17.55)
Week 8 (n=71,63,69,71,68)	-2.42 (-22.75 to 23.25)	-6 (-23.09 to 14.89)	-31.43 (-44.11 to -15.88)	-43.15 (-54.57 to -28.86)
Week 12 (n=67,62,68,71,64)	14.85 (-11.16 to 48.48)	4.51 (-18.02 to 33.25)	-20.4 (-38.61 to 3.22)	-15.96 (-33.12 to 5.6)

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: percent change				

geometric mean (confidence interval 90%)				
Week 4 (n=67,64,69,71,65)	-17.7 (-30.08 to -3.13)			
Week 8 (n=71,63,69,71,68)	-22.7 (-36.72 to -5.59)			
Week 12 (n=67,62,68,71,64)	2.31 (-18.48 to 28.42)			

Statistical analyses

Statistical analysis title	PF-00547659 7.5 mg vs placebo, Week 4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.9328
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	6.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-118.6
upper limit	131.41

Statistical analysis title	PF-00547659 22.5 mg vs placebo, Week 4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.8962
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-9.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-132.91
upper limit	113.39

Statistical analysis title	PF-00547659 75 mg vs placebo, Week 4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.8775
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	11.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-110.83
upper limit	133.74

Statistical analysis title	PF-00547659 225 mg vs placebo, Week 4
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.8224
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-17
Confidence interval	
level	90 %
sides	2-sided
lower limit	-142.02
upper limit	107.94

Statistical analysis title	PF-00547659 7.5 mg vs placebo, Week 8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg

Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.4831
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-52.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-176.48
upper limit	71.02

Statistical analysis title	PF-00547659 22.5 mg vs placebo, Week 8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1183
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-115.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-236.63
upper limit	6.13

Statistical analysis title	PF-00547659 75 mg vs placebo, Week 8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1139
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-115.8

Confidence interval	
level	90 %
sides	2-sided
lower limit	-236.29
upper limit	4.69

Statistical analysis title	PF-00547659 225 mg vs placebo, Week 8
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1931
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-96.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-218.17
upper limit	25.46

Statistical analysis title	PF-00547659 7.5 mg vs placebo, Week 12
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1182
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-119.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-245.66
upper limit	6.32

Statistical analysis title	PF-00547659 22.5 mg vs placebo, Week 12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.5784
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-41.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-165.34
upper limit	81.87

Statistical analysis title	PF-00547659 75 mg vs placebo, Week 12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0279
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-163.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-285.84
upper limit	-41.29

Statistical analysis title	PF-00547659 225 mg vs placebo, Week 12

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1053
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-123.5

Confidence interval	
level	90 %
sides	2-sided
lower limit	-249
upper limit	1.93

Secondary: Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score at Week 12

End point title	Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score at Week 12

End point description:

IBDQ: Psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QOL) in subjects with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. "n" signifies the number of evaluable subjects at the specified time point.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	72	71
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline (BL) (n=69,68,65,71,66)	128 (± 30.69)	122.1 (± 38.82)	133.4 (± 34.79)	128 (± 32.42)
Change at W12 (n=62,55,61,64,54)	19.8 (± 34.08)	20.1 (± 35.24)	32.7 (± 34.1)	32.1 (± 31.7)

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline (BL) (n=69,68,65,71,66)	132.3 (± 36.84)			
Change at W12 (n=62,55,61,64,54)	36.2 (± 29.45)			

Statistical analyses

Statistical analysis title	PF-00547659 7.5 mg vs pbo, W12 change from BL
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.8302
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-1.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.507
upper limit	7.317

Statistical analysis title	PF-00547659 22.5 mg vs pbo, W12 change from BL
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0141
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	12.33
Confidence interval	
level	90 %
sides	2-sided
lower limit	4.084
upper limit	20.567

Statistical analysis title	PF-00547659 75 mg vs pbo, W12 change from BL
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg

Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0182
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	11.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	3.564
upper limit	19.84

Statistical analysis title	PF-00547659 225 mg vs pbo, W12 change from BL

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0026
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	15.48
Confidence interval	
level	90 %
sides	2-sided
lower limit	7.056
upper limit	23.907

Secondary: Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores at Week 12

End point title	Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores at Week 12

End point description:

IBDQ: Psychometrically validated PRO instrument for measuring disease-specific QOL in subjects with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. There are 4 individual domains under the IBDQ: bowel function (fx)/symptoms (score range of 10-70), systemic symptoms (score range of 5-35), emotional (emot) status/fx (score range of 12-84), and social fx (score range of 5-35). As with total score, higher scores indicate better QOL in that domain. "n" signifies the number of evaluable subjects at the specified time point for that specific domain.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	72	71
Units: units on a scale				
arithmetic mean (standard deviation)				
BL, bowel fx (n=69,68,65,71,66)	38.9 (± 9.96)	37 (± 12.23)	41.7 (± 10.6)	38.5 (± 9.95)
Change at W12, bowel fx (n=62,55,61,64,54)	7.4 (± 11.93)	6.9 (± 12.51)	11.3 (± 11.05)	11.8 (± 12.07)
BL, emotional fx (n=69,68,65,71,66)	50.4 (± 12.6)	48.4 (± 15.39)	51.2 (± 14.7)	50.4 (± 13.73)
Change at W12, emotional fx (n=62,55,61,64,54)	5.9 (± 11.91)	6.6 (± 12.22)	10.8 (± 13.85)	10 (± 12.04)
BL, systemic symptoms (SS) (n=69,68,65,71,66)	18.1 (± 5.62)	18.2 (± 6.81)	19.6 (± 5.98)	18.4 (± 6.42)
Change at W12, SS (n=62,55,61,64,54)	3.3 (± 6.67)	3.1 (± 5.95)	4.7 (± 5.91)	4.9 (± 5.49)
BL, social fx (n=69,68,65,71,66)	20.6 (± 7.87)	18.5 (± 8.07)	20.9 (± 7.37)	20.7 (± 6.99)
Change at W12, social fx (n=62,55,61,64,54)	3.3 (± 6.27)	3.6 (± 7.33)	5.9 (± 6.51)	5.4 (± 6.9)

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: units on a scale				
arithmetic mean (standard deviation)				
BL, bowel fx (n=69,68,65,71,66)	41 (± 11.37)			
Change at W12, bowel fx (n=62,55,61,64,54)	12.8 (± 11.45)			
BL, emotional fx (n=69,68,65,71,66)	51.3 (± 15.92)			
Change at W12, emotional fx (n=62,55,61,64,54)	12 (± 11.4)			
BL, systemic symptoms (SS) (n=69,68,65,71,66)	19 (± 5.97)			
Change at W12, SS (n=62,55,61,64,54)	4.8 (± 5.05)			
BL, social fx (n=69,68,65,71,66)	20.9 (± 7.73)			
Change at W12, social fx (n=62,55,61,64,54)	6.6 (± 6.58)			

Statistical analyses

Statistical analysis title	PF-00547659 7.5 mg vs pbo, bowel fx, W12 change

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 7.5 mg

Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.6862
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.73
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.689
upper limit	2.235

Statistical analysis title	PF-00547659 22.5 mg vs pbo, bowel fx, W12 change
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0135
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	4.37
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.467
upper limit	7.28

Statistical analysis title	PF-00547659 75 mg vs pbo, bowel fx, W12 change
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0171
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	4.16

Confidence interval	
level	90 %
sides	2-sided
lower limit	1.293
upper limit	7.023

Statistical analysis title	PF-00547659 225 mg vs pbo, bowel fx, W12 change
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0041
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	5.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	2.232
upper limit	8.172

Statistical analysis title	PF-00547659 7.5 mg vs pbo, emot fx, W12 change
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.9072
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	0.22
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.897
upper limit	3.339

Statistical analysis title	PF-00547659 22.5 mg vs pbo, emot fx, W12 change

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0161
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	4.47
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.42
upper limit	7.522

Statistical analysis title	PF-00547659 75 mg vs pbo, emot fx, W12 change

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0271
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	4.06
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.042
upper limit	7.071

Statistical analysis title	PF-00547659 225 mg vs pbo, emot fx, W12 change

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.002
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	5.9

Confidence interval	
level	90 %
sides	2-sided
lower limit	2.778
upper limit	9.026

Statistical analysis title	PF-00547659 7.5 mg vs pbo, SS, W12 change
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.7711
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.26
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.756
upper limit	1.229

Statistical analysis title	PF-00547659 22.5 mg vs pbo, SS, W12 change
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0582
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	1.69
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.223
upper limit	3.147

Statistical analysis title	PF-00547659 75 mg vs pbo, SS, W12 change

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0558
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	1.68
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.235
upper limit	3.12

Statistical analysis title	PF-00547659 225 mg vs pbo, SS, W12 change

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0686
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	1.66
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.161
upper limit	3.153

Statistical analysis title	PF-00547659 7.5 mg vs pbo, social fx, W12 change

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.7561
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	-0.33

Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.094
upper limit	1.429

Statistical analysis title	PF-00547659 22.5 mg vs pbo, social fx, W12 change
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	145
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0384
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	2.17
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.447
upper limit	3.891

Statistical analysis title	PF-00547659 75 mg vs pbo, social fx, W12 change
Statistical analysis description:	
LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.	
Comparison groups	Placebo v PF-00547659 75 mg
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0729
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	1.86
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.154
upper limit	3.557

Statistical analysis title	PF-00547659 225 mg vs pbo, social fx, W12 change

Statistical analysis description:

LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.

Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	143
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.006
Method	Mixed models analysis
Parameter estimate	LSM Difference
Point estimate	2.95
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.19
upper limit	4.715

Secondary: Percentage of subjects with an Inflammatory Bowel Disease Questionnaire (IBDQ) total score of more than or equal to (>=) 170 at Week 12

End point title	Percentage of subjects with an Inflammatory Bowel Disease Questionnaire (IBDQ) total score of more than or equal to (>=) 170 at Week 12

End point description:

IBDQ: Psychometrically validated PRO instrument for measuring disease-specific QOL in subjects with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. A score of >=170 corresponds to clinical remission.

End point type	Secondary

End point timeframe:

Week 12

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	65	57	63	64
Units: percentage of subjects				
number (confidence interval 90%)	36.9 (27.4 to 47.5)	36.8 (26.9 to 47.9)	55.6 (45 to 66.3)	46.9 (36.1 to 57.5)

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	54			
Units: percentage of subjects				
number (confidence interval 90%)	48.1 (36.3 to 59.4)			

Statistical analyses

Statistical analysis title	PF-00547659 7.5 mg vs placebo
Comparison groups	Placebo v PF-00547659 7.5 mg
Number of subjects included in analysis	122
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.5201 [32]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	-0.002
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.145
upper limit	0.142

Notes:

[32] - 1-sided p-value

Statistical analysis title	PF-00547659 22.5 mg vs placebo
Comparison groups	Placebo v PF-00547659 22.5 mg
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0217 [33]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.183
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.039
upper limit	0.328

Notes:

[33] - 1-sided p-value

Statistical analysis title	PF-00547659 75 mg vs placebo
Comparison groups	Placebo v PF-00547659 75 mg

Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1473 [34]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.096
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.045
upper limit	0.237

Notes:

[34] - 1-sided p-value

Statistical analysis title	PF-00547659 225 mg vs placebo
Comparison groups	Placebo v PF-00547659 225 mg
Number of subjects included in analysis	119
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.1231 [35]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	0.112
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.038
upper limit	0.261

Notes:

[35] - 1-sided p-value

Secondary: Number of subjects with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and withdrawals due to TEAEs during the treatment period (Weeks 0-12)

End point title	Number of subjects with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and withdrawals due to TEAEs during the treatment period (Weeks 0-12)

End point description:

An adverse event (AE) was any untoward medical occurrence attributed to study drug in a subject who received study drug. TEAEs are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs.An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

End point type	Secondary

End point timeframe:

Screening through to end of treatment period, up to 12 weeks

End point values	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	73	71	72[36]	71[37]
Units: subjects				
number (not applicable)				
With TEAEs	39	41	36	43
With SAEs	4	11	1	3
Withdrawals due to TEAEs	2	6	0	3

Notes:

[36] - 2 subjects in this group were counted under 75 mg group for safety as they received 75 mg instead.
[37] - 2 subjects in the 22.5 mg group were counted under the 75 mg group for safety

End point values	PF-00547659 225 mg			
Subject group type	Reporting group			
Number of subjects analysed	70			
Units: subjects				
number (not applicable)				
With TEAEs	43			
With SAEs	3			
Withdrawals due to TEAEs	1			

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum serum PF-00547659 concentration achieved

End point title	Maximum serum PF-00547659 concentration achieved[38]

End point description:

End point type	Secondary

End point timeframe:

Weeks 0 (baseline), 2, 4, 8, 12, 16, 20, 24, 28, 32, and 36; Early Withdrawal

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: According to the protocol, all samples from placebo-treated subjects may not have been analyzed.

End point values	PF-00547659 7.5 mg	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	67	67	68	62
Units: nanograms (ng)/milliliter (mL)				
arithmetic mean (standard deviation)	929.4 (± 1977.8)	2062 (± 1395.5)	6576 (± 2146)	21470 (± 4788.4)

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Screening till Week 36 or Early Withdrawal, whichever was later.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	18.1

Reporting groups

Reporting group title	Placebo

Reporting group description:

Subjects received placebo in the form of 3 subcutaneous (SC)
injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 centimeters (cm) apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Reporting group title	PF-00547659 7.5 mg

Reporting group description:

Subjects received PF-00547659 7.5 milligrams(mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Reporting group title	PF-00547659 22.5 mg

Reporting group description:

Subjects received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28,
and 56, following the completion of most study procedures. Subjects were administered PF-00547659 22.5 mg SC in
the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Reporting group title	PF-00547659 75 mg

Reporting group description:

Subjects received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 75 mg SC in
the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Reporting group title	PF-00547659 225 mg

Reporting group description:

Subjects received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Subjects were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.

Serious adverse events	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 73 (5.48%)	11 / 71 (15.49%)	2 / 70 (2.86%)
number of deaths (all causes)	0	1	0

number of deaths resulting from adverse events	0	1	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Surgical and medical procedures			
Colectomy total			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Epilepsy			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Migraine			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tension headache			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Retinal artery embolism			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Abdominal pain			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	1 / 73 (1.37%)	6 / 71 (8.45%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	2 / 73 (2.74%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 73 (1.37%)	1 / 71 (1.41%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Psychiatric disorders			
Delirium			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 73 (0.00%)	1 / 71 (1.41%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 73 (1.37%)	0 / 71 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	PF-00547659 75 mg	PF-00547659 225 mg	

Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 73 (5.48%)	3 / 70 (4.29%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Colectomy total			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Epilepsy			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			
subjects affected / exposed	1 / 73 (1.37%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tension headache			
subjects affected / exposed	0 / 73 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Retinal artery embolism			

subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 73 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ulcerative			
subjects affected / exposed	2 / 73 (2.74%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	1 / 73 (1.37%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			

Pulmonary embolism			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	0 / 73 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	1 / 73 (1.37%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	0 / 73 (0.00%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	PF-00547659 7.5 mg	PF-00547659 22.5 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	17 / 73 (23.29%)	16 / 71 (22.54%)	15 / 70 (21.43%)
Nervous system disorders			
Headache			
subjects affected / exposed	6 / 73 (8.22%)	5 / 71 (7.04%)	7 / 70 (10.00%)
occurrences (all)	8	5	15
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 73 (0.00%)	0 / 71 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	0	2
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 73 (2.74%)	6 / 71 (8.45%)	3 / 70 (4.29%)
occurrences (all)	3	6	3
Nausea			
subjects affected / exposed	3 / 73 (4.11%)	6 / 71 (8.45%)	1 / 70 (1.43%)
occurrences (all)	3	7	1
Vomiting			
subjects affected / exposed	3 / 73 (4.11%)	1 / 71 (1.41%)	4 / 70 (5.71%)
occurrences (all)	4	1	4
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	4 / 73 (5.48%)	1 / 71 (1.41%)	0 / 70 (0.00%)
occurrences (all)	4	1	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	3 / 73 (4.11%)	0 / 71 (0.00%)	3 / 70 (4.29%)
occurrences (all)	3	0	4

Non-serious adverse events	PF-00547659 75 mg	PF-00547659 225 mg	
Total subjects affected by non-serious adverse events subjects affected / exposed	14 / 73 (19.18%)	18 / 70 (25.71%)	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	4 / 73 (5.48%) 4	8 / 70 (11.43%) 12	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	4 / 73 (5.48%) 4	2 / 70 (2.86%) 2	
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all)	2 / 73 (2.74%) 3 1 / 73 (1.37%) 1 0 / 73 (0.00%) 0	1 / 70 (1.43%) 1 4 / 70 (5.71%) 4 2 / 70 (2.86%) 3	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 73 (1.37%) 1	0 / 70 (0.00%) 0	
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	5 / 73 (6.85%) 5	4 / 70 (5.71%) 4	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
04 March 2013	Updated exclusion criterion to exclude subjects with diagnosis of ischaemic colitis, radiation colitis, diverticular disease associated with colitis, and microscopic colitis
18 March 2013	Corrected duration of subject participation from approximately 38 months to 28 months; Updated exclusion criteria; Clarified that unblinded preparer may also administer investigational drug to subject(s) and that no unblinded personnel may participate in evaluation of subject(s); Blood volume section revision; Revision to allow other qualified physicians to read radiograph; References to procedures for additional pharmacokinetic sampling for only Japanese subjects in Japan removed due to Japan not participating in this study; Other updates to align with current protocol template including section on Data Monitoring Committee

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported